Plasmodium sensitivity to artemisinins: Magic bullets hit elusive targets

Trends in Parasitology

Volumn 27, Issue 2, 2011, Pages 73-81

  Ding, Xavier C ^a   Beck, Hans Peter ^b,c   Raso, Giovanna ^a,b,c  

^a CENTRE SUISSE DE RECHERCHES SCIENTIFIQUES EN CÔTE D'IVOIRE   (Côte d’Ivoire)

^b SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; BENFLUMETOL; CHLOROQUINE; THAPSIGARGIN; TUMOR PROTEIN;

ARTEMISIA ANNUA; ASSOCIATION; BACTERIAL GENE; DISEASE ASSOCIATION; DNA POLYMORPHISM; GENE MUTATION; GENETIC MARKER; MALARIA; MALARIA CONTROL; MALARIA FALCIPARUM; NONHUMAN; PARASITEMIA; PHENOTYPE; REVIEW; SACCHAROMYCES CEREVISIAE;

ANIMALS; ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; PLASMODIUM; POLYMORPHISM, GENETIC;

EID: 79251599335     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.11.006     Document Type: Review

References (92)

1. Taylor W.R., White N.J. Antimalarial drug toxicity: a review. Drug Saf. 2004, 27:25-61.
2. Efferth T., Kaina B. Toxicity of the antimalarial artemisinin and its dervatives. Crit. Rev. Toxicol. 2010, 40:405-421.
3. Dondorp A.M., et al. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol. 2010, 8:272-280.
4. Krishna S., et al. Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol. Med. 2006, 12:200-205.
5. Li J., Zhou B. Biological actions of artemisinin: insights from medicinal chemistry studies. Molecules 2010, 15:1378-1397.
6. Meshnick S.R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 2002, 32:1655-1660.
7. Golenser J., et al. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol. 2006, 36:1427-1441.
8. O'Neill P.M., et al. The molecular mechanism of action of artemisinin--the debate continues. Molecules 2010, 15:1705-1721.
9. Olliaro P.L., et al. Possible modes of action of the artemisinin-type compounds. Trends Parasitol. 2001, 17:122-126.
10. Meunier B., Robert A. Heme as Trigger and Target for Trioxane-Containing Antimalarial Drugs (dagger). Acc. Chem. Res. 2010, 43:1444-1451. 10.1021/ar100070k.
11. Haynes R.K., et al. Highly antimalaria-active artemisinin derivatives: biological activity does not correlate with chemical reactivity. Angew. Chem. Int. Ed. Engl. 2004, 43:1381-1385.
12. Eckstein-Ludwig U., et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003, 424:957-961.
13. Asawamahasakda W., et al. Reaction of antimalarial endoperoxides with specific parasite proteins. Antimicrob. Agents Chemother. 1994, 38:1854-1858.
14. Bhisutthibhan J., et al. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J. Biol. Chem. 1998, 273:16192-16198.
15. Bhisutthibhan J., Meshnick S.R. Immunoprecipitation of [(3)H]dihydroartemisinin translationally controlled tumor protein (TCTP) adducts from Plasmodium falciparum-infected erythrocytes by using anti-TCTP antibodies. Antimicrob. Agents Chemother. 2001, 45:2397-2399.
16. Walker D.J., et al. Mechanisms of artemisinin resistance in the rodent malaria pathogen Plasmodium yoelii. Antimicrob. Agents Chemother. 2000, 44:344-347.
17. Uhlemann A.C., et al. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat. Struct. Mol. Biol. 2005, 12:628-629.
18. Valderramos S.G., et al. Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob. Agents Chemother. 2010, 54:3842-3852.
19. O'Neill P.M., et al. Enantiomeric 1,2,4-trioxanes display equivalent in vitro antimalarial activity versus Plasmodium falciparum malaria parasites: implications for the molecular mechanism of action of the artemisinins. Chembiochem 2005, 6:2048-2054.
20. Jefford C.W., et al. Synthesis, structure, and antimalarial activity of some enantiomerically pure, cis-fused cyclopenteno-1,2,4-trioxanes. Helvetica Chimica Acta 1995, 78:647-662.
21. Li W., et al. Yeast model uncovers dual roles of mitochondria in action of artemisinin. PLoS Genet. 2005, 1:e36.
22. Wang J., et al. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS ONE 2010, 5:e9582.
23. Natalang O., et al. Dynamic RNA profiling in Plasmodium falciparum synchronized blood stages exposed to lethal doses of artesunate. BMC Genomics 2008, 9:388.
24. Witkowski B., et al. Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism. Antimicrob. Agents Chemother. 2010, 54:1872-1877.
25. Valderramos S.G., Fidock D.A. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol. Sci. 2006, 27:594-601.
26. Anderson T.J.C., et al. Are transporter genes other than the chloroquine resistance locus (pfcrt) and multidrug resistance gene (pfmdr) associated with antimalarial drug resistance?. Antimicrob. Agents Chemother. 2005, 49:2180-2188.
27. Hunt P., et al. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Mol. Microbiol. 2007, 65:27-40.
28. Carlton J.M., et al. Of mice and malaria mutants: unravelling the genetics of drug resistance using rodent malaria models. Trends Parasitol. 2001, 17:236-242.
29. Dondorp A.M., et al. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med. 2009, 361:455-467.
30. Noedl H., et al. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med. 2008, 359:2619-2620.
31. Noedl H., et al. Artemisinin-resistant malaria in Asia. N. Engl. J. Med. 2009, 361:540-541.
32. Thanh, N.V. et al. (2010) Monitoring for Plasmodium falciparum drug resistance to artemisinin and artesunate in Binh Phuoc Province, Vietnam: 1998-2009. Malaria Journal 2010 9:181 9, 181.
33. Imwong M., et al. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob. Agents Chemother. 2010, 54:2886-2892.
34. Gardner M.J., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002, 419:498-511.
35. Jambou R., et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet 2005, 366:1960-1963.
36. Jambou R., et al. Geographic structuring of the Plasmodium falciparum sarco(endo)plasmic reticulum Ca2+ ATPase (PfSERCA) gene diversity. PLoS ONE 2010, 5:e9424.
37. Mugittu, K. et al. (2006) Molecular monitoring of Plasmodium falciparum resistance to artemisinin in Tanzania. Malaria Journal 2009 8:31 5, 126.
38. Ferreira I.D., et al. In vitro assessment of artesunate, artemether and amodiaquine susceptibility and molecular analysis of putative resistance-associated mutations of Plasmodium falciparum from São Tomé and Príncipe. Trop. Med. Int. Health 2007, 12:353-362.
39. Cojean S., et al. Resistance to dihydroartemisinin. Emerging. Infect. Dis. 2006, 12:1798-1799.
40. Eshetu T., et al. Different mutation patterns of Plasmodium falciparum among patients in Jimma University Hospital, Ethiopia. Malar. J. 2010, 9:226.
41. Legrand E., et al. Resistance to dihydroartemisinin. Emerging. Infect. Dis. 2007, 13:808-809. author reply 809.
42. Price R.N., et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004, 364:438-447.
43. Price R.N., et al. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Antimicrob. Agents Chemother. 1999, 43:2943-2949.
44. Pickard A.L., et al. Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob. Agents and Chemother. 2003, 47:2418-2423.
45. Lim, P. et al. (2009) Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malaria Journal 2009 8:31 8, 11.
46. Alker A.P., et al. Pfmdr1 and in vivo resistance to artesunate-mefloquine in falciparum malaria on the Cambodian-Thai border. Am. J. Trop. Med. Hyg. 2007, 76:641-647.
47. Price R.N., et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin. Infect. Dis. 2006, 42:1570-1577.
48. Beez D., et al. Genetic predisposition favors the acquisition of stable artemisinin resistance in malaria parasites. Antimicrob. Agents Chemother. 2010, published online ahead of print on 1 November 2010, DOI: 10.1128/AAC.00916-10.
49. Andriantsoanirina V., et al. Plasmodium falciparum drug resistance in Madagascar: facing the spread of unusual pfdhfr and pfmdr-1 haplotypes and the decrease of dihydroartemisinin susceptibility. Antimicrob. Agents Chemother. 2009, 53:4588-4597.
50. Randrianarivelojosia M., et al. Madagascan isolates of Plasmodium falciparum showing low sensitivity to artemether in vitro. Ann. Trop. Med. Parasitol. 2001, 95:237-243.
51. Ngo T., et al. Analysis of pfcrt, pfmdr1, dhfr, and dhps mutations and drug sensitivities in Plasmodium falciparum isolates from patients in Vietnam before and after treatment with artemisinin. Am. J. Trop. Med. Hyg. 2003, 68:350-356.
52. Sidhu A.B., et al. Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science 2002, 298:210-213.
53. Cooper R.A., et al. Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol. Pharmacol. 2002, 61:35-42.
54. Valderramos S.G., et al. Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum. PLoS Pathog. 2010, 6:e1000887.
55. Reed M.B., et al. Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature 2000, 403:906-909.
56. Duraisingh M.T., et al. Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol. Microbiol. 2000, 36:955-961.
57. Sidhu A.B., et al. Decreasing pfmdr1 copy number in Plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J. Infect. Dis. 2006, 194:528-535.
58. Chavchich M., et al. Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum. Antimicrob. Agents Chemother. 2010, 54:2455-2464.
59. Chen, N. et al. (2010) De-amplification of pfmdr1-containing amplicon on chromosome 5 in Plasmodium falciparum is associated with reduced resistance to artelinic acid in vitro. Antimicrobial Agents and Chemotherapy, 10.1128/AAC.01421-01409.
60. Ferrer-Rodríguez I., et al. Plasmodium yoelii: identification and partial characterization of an MDR1 gene in an artemisinin-resistant line. J. Parasitol. 2004, 90:152-160.
61. Afonso A., et al. Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob. Agents Chemother. 2006, 50:480-489.
62. Hunt P., et al. Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites. BMC Genomics 2010, 11:499.
63. Rodrigues L.A., et al. Experimental Evolution of Resistance to Artemisinin Combination Therapy Results in Amplification of the mdr1 Gene in a Rodent Malaria Parasite. PLoS ONE 2010, 5:e11593.
64. Anderson T.J., et al. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J. Infect. Dis. 2010, 201:1326-1330.
65. Hoshen M.B., et al. Mathematical modelling of the chemotherapy of Plasmodium falciparum malaria with artesunate: postulation of 'dormancy', a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology 2000, 121(Pt 3):237-246.
66. Nagamune K., et al. Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis. Antimicrob. Agents Chemother. 2007, 51:3816-3823.
67. Liao F. Discovery of artemisinin (Qinghaosu). Molecules 2009, 14:5362-5366.
68. Hsu E., Hsu E. Reflections on the 'discovery' of the antimalarial qinghao. Br. J. Clin. Pharmacol. 2006, 61:666-670.
69. Klayman D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 1985, 228:1049-1055.
70. Kindermans J.M., et al. Ensuring sustained ACT production and reliable artemisinin supply. Malar. J. 2007, 6:125.
71. Liu C., et al. Artemisinin: current state and perspectives for biotechnological production of an antimalarial drug. Appl. Microbiol. Biotechnol. 2006, 72:11-20.
72. Vennerstrom J.L., et al. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004, 430:900-904.
73. Eastman R.T., Fidock D.A. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat. Rev. Microbiol. 2009, 7:864-874.
74. Mita T., et al. Spread and evolution of Plasmodium falciparum drug resistance. Parasitol. Int. 2009, 58:201-209.
75. Ferone R., et al. Altered dihydrofolate reductase associated with drug-resistance transfer between rodent plasmodia. Science 1970, 167:1263-1264.
76. Wilson C.M., et al. Amplification of pfmdr 1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol. Biochem. Parasitol. 1993, 57:151-160.
77. Kan S.C., Siddiqui W.A. Comparative studies on dihydrofolate reductases from Plasmodium falciparum and Aotus trivirgatus. J. Protozool. 1979, 26:660-664.
78. Young M., et al. Drug resitance In Plasmodium falciparum from Thailand. Am. J. Trop. Med. Hyg. 1963, 12:305-314.
79. Eyles D., et al. Plasmodium falciparum resistant to chloroquine in Cambodia. Am. J. Trop. Med. Hyg. 1963, 12:840-843.
80. Björkman A., Phillips-Howard P.A. Drug-resistant malaria: mechanisms of development and inferences for malaria control. Trans. R. Soc. Trop. Med. Hyg. 1990, 84:323-324.
81. WHO (2006) Guidelines for the Treatment of Malaria.
82. Duraisingh M.T., et al. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol. Biochem. Parasitol. 2000, 108:13-23.
83. Sidhu A.B., Fidock D.A. pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol. Microbiol. 2005, 57:913-926.
84. Noedl H., et al. Artemisinin resistance in cambodia: a clinical trial designed to address an emerging problem in southeast Asia. Clin. Infect. Dis. 2010, 51:e82-89.
85. Tahar R., et al. Molecular epidemiology of malaria in Cameroon. XXVIII. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum and sequence analysis of the P. falciparum ATPase 6 gene. Am. J. Trop. Med. Hyg. 2009, 81:13-18.
86. Muangnoicharoen S., et al. Role of known molecular markers of resistance in the antimalarial potency of piperaquine and dihydroartemisinin in vitro. Antimicrob. Agents Chemother. 2009, 53:1362-1366.
87. Basco L.K., Ringwald P. Molecular epidemiology of malaria in Cameroon. X. Evaluation of PFMDR1 mutations as genetic markers for resistance to amino alcohols and artemisinin derivatives. Am. J. Trop. Med. Hyg. 2002, 66:667-671.
88. Nsobya S.L., et al. Resistance-mediating Plasmodium falciparum pfcrt and pfmdr1 alleles after treatment with artesunate-amodiaquine in Uganda. Antimicrob. Agents Chemother. 2007, 51:3023-3025.
89. Sisowath C., et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop. Med. Int. Health 2007, 12:736-742.
90. Dokomajilar C., et al. Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda where malaria is highly endemic. Antimicrob. Agents Chemother. 2006, 50:1893-1895.
91. Humphreys G.S., et al. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob. Agents Chemother. 2007, 51:991-997.
92. Zongo I., et al. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 2007, 369:491-498.